Donation

TV Blog Categories
Dr. Nizar Bahlis ASH abstract on MagnetisMM-3
ASH
Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma: MagnetisMM-3
Dr. Noopur Raje ASH abstract MagnetisMM-1
ASH
Elranatamab Induces Durable Responses for Patients with Relapsed or Refractory Multiple Myeloma
Dr. Ashley Rosko on factors that influence transplant and survival
ASH
Multiple Myeloma Transplant: Examining the Intersection of Access, Age and Race
Is there a new highly sensitive blood test to detect minimal residual disease?
Ask Dr. Durie
Is there a new highly sensitive blood test to detect minimal residual disease? 
Are mass spectrometry and next-generation flow useful tests to evaluate minimal residual disease (MRD)?
Ask Dr. Durie
Are mass spectrometry and next-generation flow useful tests to evaluate minimal residual disease (MRD)?
Dr. Tondre Buck abstract on race and myeloma risk assessment
ASH
Real-World Multiple Myeloma Risk Factors and Outcomes By Race/Ethnicity in the United States

Give Where Most Needed

Learn More